Last update 01 Nov 2024

Ascendis Pharma Growth Disorders A/S

Subsidiary Company|
Denmark

Overview

Tags

Congenital Disorders
Skin and Musculoskeletal Diseases
Other Diseases
Recombinant polypeptide
Hormone

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Endocrinology and Metabolic Disease2
Nervous System Diseases1
Top 5 Drug TypeCount
Hormone1
Recombinant polypeptide1
Top 5 TargetCount
GR(Glucocorticoid receptor)1
NPRC(Natriuretic peptide receptor 3)1

Related

2
Drugs associated with Ascendis Pharma Growth Disorders A/S
Lonapegsomatropin-tcgd
Target
GR
Mechanism
GR agonists
Active Org.
Ascendis Pharma Endocrinology Division A/S [+4]
Originator Org.
Ascendis Pharma A/SAscendis Pharma A/S
Active Indication
Growth hormone deficiency [+3]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date25 Aug 2021
Navepegritide
Target
NPRC
Mechanism
NPRC agonists
Active Org.
VISEN Pharmaceuticals (Shanghai) Co., Ltd.VISEN Pharmaceuticals (Shanghai) Co., Ltd. [+2]
Originator Org.
Ascendis Pharma A/SAscendis Pharma A/S
Active Indication
Achondroplasia
Inactive Indication-
Drug Highest PhasePhase 2/3
First Approval Ctry. / Loc.-
First Approval Date-
11
Clinical Trials associated with Ascendis Pharma Growth Disorders A/S
CTIS2023-508341-40-00
/ Recruiting
COACH: A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children with Achondroplasia - ASND0042
NCT06433557
/ RecruitingPhase 2
A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children With Achondroplasia
CTIS2022-502202-33-00
/ Recruiting
AttaCH: A Phase 2, Multicenter, Long-Term, Open Label Extension Trial Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children and Adolescents with Achondroplasia - ASND0039
100 Clinical Results associated with Ascendis Pharma Growth Disorders A/S
Login to view more data
0 Patents (Medical) associated with Ascendis Pharma Growth Disorders A/S
Login to view more data
100 Deals associated with Ascendis Pharma Growth Disorders A/S
Login to view more data
100 Translational Medicine associated with Ascendis Pharma Growth Disorders A/S
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2 Clinical
1
1
Phase 3 Clinical
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Navepegritide
 ( NPRC )		Achondroplasia
More
Phase 3 Clinical
Lonapegsomatropin-tcgd
 ( GR )		Achondroplasia
More
Phase 2
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free